Anti-Cancer Drug Design

Bioreductive drugs into the next millennium
pp. 519-528(10)
Authors: Stratford, IJ; Workman, P

Tirapazamine: laboratory data relevant to clinical activity
pp. 529-539(11)
Authors: Brown, JM; Wang, L-H

Enzymology of tirapazamine metabolism: a review
pp. 541-573(33)
Authors: Patterson, AV; Saunders, MP; Chinje, EC; Patterson, LH; Stratford, IJ

1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity
pp. 575-592(18)
Authors: Kelson, AB; McNamara, JP; Pandey, A; Ryan, KJ; Dorie, MJ; McAfee, PA; Menke, DR; Brown, JM; Tracy, M

Targeting hypoxia with a new generation of indolequinones
pp. 593-609(17)
Authors: Jaffar, M; Naylor, MA; Robertson, N; Stratford, IJ

Cyclopropyl indolequinones: mechanistic probes for bioreductive anticancer drug action
pp. 611-634(24)
Authors: Moody, CJ; Norton, CL; Slawin, AMZ; Taylor, S

Indolequinone bioreductive drugs: kinetic factors which influence selectivity for hypoxia
pp. 635-653(19)
Authors: Everett, SA; Naylor, MA; Nolan, J; Patel, KB; Wardman, P

The 5-nitrofuran-2-ylmethylidene group as a potential bioreductively activated prodrug system for diol-containing drugs
pp. 655-662(8)
Authors: Mahmud, NP; Garrett, SW; Threadgill, MD

Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts
pp. 663-685(23)
Authors: Wilson, WR; Tercel, M; Anderson, RF; Denny, WA

Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia
pp. 687-702(16)
Author: Hodgkiss, RJ

Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl)aceta mide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography
pp. 703-730(28)
Authors: Aboagye, EO; Kelson, AB; Tracy, M; Workman, P

Altered efficacy and selectivity of tyrosine kinase inhibitors of the activated states of protein tyrosine kinases
pp. 731-734(4)
Authors: Levitzki, A; Böhmer, FD